Longitudinal Follow-Up of a Prospective Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma Reveals Distinct Patterns of Survivorship

HPB - United Kingdom
doi 10.1016/j.hpb.2019.03.095

Related search